BAM-15: The Complete Guide to BAM-15 Mitochondrial Uncoupler

Quick Facts

What BAM-15 Does & How It Works

A Note on Classification

BAM-15 is covered in the MPP research compound library because it is discussed in the same communities (metabolic health research, performance optimization, biohacking) where peptide research compounds circulate, and because understanding what it is and what it is not serves that audience well. It is not a peptide. It has no amino acid sequence and no peptide bonds. It belongs to the oxadiazolopyrazine chemical class. Where other articles in this library describe peptide mechanisms, this one describes the mechanism of a small-molecule protonophore: a different type of compound with a fundamentally different mechanism.

What BAM-15 Does: Functional Outcomes

These are the effects documented in preclinical research. None have been confirmed in human studies.

• Increases whole-body energy expenditure by forcing mitochondria to burn fuel as heat rather than capturing it as ATP
• Reduces fat mass in obese animal models without requiring reduced caloric intake
• Preserves lean body mass throughout treatment periods studied in animals
• Reverses glucose intolerance and normalizes insulin levels in diet-induced obese mouse models
• Reduces liver triglyceride content in animal models, consistent with the compound's hepatic distribution
• Activates AMPK, promoting downstream glucose uptake, fatty acid oxidation, and mitochondrial biogenesis

How BAM-15 Works: Mechanism of Action

Protonophore Activity: Mitochondrial Proton Leak (Evidence: In vitro and Animal)

The inner mitochondrial membrane normally acts as a tight barrier for protons. The electron transport chain pumps protons across this membrane to create an electrochemical gradient (an electrical and chemical pressure difference across the membrane that stores energy). That gradient drives ATP synthase to produce ATP. BAM-15 inserts into the inner mitochondrial membrane and acts as a proton carrier, shuttling protons back across without passing through ATP synthase. This dissipates the gradient continuously, forcing the cell to run its electron transport chain faster to maintain ATP levels. The result is a sustained increase in oxygen consumption and substrate oxidation. The energy that would have been captured as ATP is released as heat instead, a process called proton leak-driven thermogenesis .

AMPK Activation as a Secondary Metabolic Driver (Evidence: Animal)

When ATP synthesis is impaired by uncoupling, the ratio of AMP to ATP inside the cell rises. That rising AMP-to-ATP ratio triggers AMPK (AMP-activated protein kinase), a cellular energy sensor that functions as a master metabolic switch. Activated AMPK promotes glucose uptake into muscle and other peripheral tissues, stimulates fatty acid oxidation, inhibits lipid synthesis, and drives mitochondrial biogenesis. This secondary AMPK activation appears to extend BAM-15's metabolic effects beyond the window predicted by its short half-life. The result is a sustained metabolic shift that outlasts the acute uncoupling phase .

Selective Mitochondrial Targeting: Distinction from DNP (Evidence: In vitro)

The classic mitochondrial uncoupler DNP is non-selective. It disrupts proton gradients across any lipid bilayer (the double-layer membrane that forms the boundary of cells and organelles) it encounters, including the plasma membrane, which creates widespread cellular toxicity at therapeutic doses. BAM-15 shows preferential activity at the inner mitochondrial membrane at effective concentrations, with no evidence of plasma membrane depolarization in studied concentration ranges. This selectivity is the mechanistic basis for BAM-15's improved preclinical tolerability profile relative to DNP and is a primary focus of research establishing BAM-15 as a next-generation uncoupler candidate .

BAM-15 Molecular Profile

Structure reference: View BAM-15 on PubChem - Publishing team: retrieve 2D structure image from this link.

BAM-15 Uses & Benefits

BAM-15 is a preclinical research compound. The uses documented below reflect what has been studied in animal and cell models. None of these uses have been validated in human clinical trials.

Metabolic Obesity Research

Researchers working on metabolic dysfunction and obesity have investigated BAM-15 as a tool for studying mitochondrial energy expenditure as a treatment approach. In diet-induced obese mouse models, BAM-15 produced dose-dependent reductions in fat mass while preserving lean tissue and without requiring reduced caloric intake. That combination distinguishes it mechanistically from most established obesity interventions. Liver triglyceride content also decreased, consistent with the compound's preferential hepatic accumulation. The preclinical profile has attracted attention as a candidate for metabolic disease drug development research. (Evidence: Preliminary: animal models, Alexopoulos et al., 2020)

Glucose Metabolism and Insulin Resistance Research

BAM-15 has been studied in the context of type 2 diabetes and insulin resistance biology, where improving mitochondrial function and AMPK activation are recognized as relevant therapeutic targets. Animal studies found complete reversal of glucose intolerance and hyperinsulinemia (abnormally high insulin levels in the blood) in diet-induced obese mice over approximately three weeks of treatment. Insulin sensitivity improved across multiple rodent models. The dual mechanism combines direct mitochondrial enhancement of glucose oxidation with AMPK-mediated glucose uptake, providing a plausible biological pathway for these findings. (Evidence: Preliminary: animal models, Alexopoulos et al., 2020)

Energy Expenditure and Thermogenesis Research

Researchers studying mitochondrial metabolism use the BAM-15 mitochondrial uncoupler as a tool for investigating proton leak-driven thermogenesis and its effects on whole-body energy balance. The compound's measurable, time-limited acute effect on oxygen consumption makes it useful as a research instrument for understanding how controlled uncoupling affects metabolic rate. It is also investigated as a potential approach for increasing caloric expenditure independent of physical activity or appetite. That framing is relevant to the broader question of whether mitochondrial uncoupling can be safely harnessed as a therapeutic strategy. (Evidence: Preliminary: animal models, Alexopoulos et al., 2020)

Cardiovascular and Endothelial Biology Research

Mitochondrial function in vascular endothelium is an active area of cardiovascular research, and BAM-15 has begun to appear in published work examining endothelial cell biology. Endothelial cells depend heavily on mitochondrial health for maintaining vascular tone, barrier integrity, and inflammatory signaling. Whether BAM-15's uncoupling mechanism produces net positive or net negative effects in endothelial tissue at human-relevant exposures is an open question; this is an early-stage research area with no clinical conclusions available. (Evidence: Preliminary: review and early preclinical, PubMed 40429748)

Where This Guide Comes From

BAM-15 Results & Timelines

The timelines below are drawn from preclinical animal studies (primarily diet-induced obese mouse models) and from pharmacokinetic data collected in rodents. No human outcome timelines have been documented in published research. The distinction matters: what happens in a mouse model over three weeks does not automatically translate to what would happen in a human over the same period.

Acute Energy Expenditure: Preclinical Timeline

• 1-2 hours post-dose: Measurable increase in whole-body oxygen consumption observed in rodent pharmacokinetic studies, the direct indicator of increased energy expenditure
• Approximately 3 hours post-dose: Oxygen consumption returns toward baseline, tracking the compound's short half-life
• Approximately 4 hours post-dose: Tissue clearance substantially complete in animal models

Metabolic and Body Composition: Preclinical Timeline

• Days of treatment: Initial reductions in fat mass begin to appear in animal models receiving consistent dosing
• Approximately 3 weeks of treatment: Complete reversal of glucose intolerance and hyperinsulinemia documented in diet-induced obese mice; notable improvements in insulin sensitivity and body composition
• Weeks of continued treatment: Sustained fat mass reduction, reduced liver triglycerides, and preserved lean mass observed throughout studied treatment periods

How to Administer BAM-15

Oral

In rodent studies, BAM-15 was administered by oral gavage (direct delivery to the stomach) at doses of 10, 50, and 100 mg/kg. Oral bioavailability was characterized at 67% in mice, which is relatively high for a lipophilic (fat-soluble, able to dissolve in and pass through fatty membranes) small molecule with limited water solubility. Research-chemical vendors sell BAM-15 in oral formats including capsule (50 mg per capsule) and liquid solution (100 mg/mL), consistent with oral administration being the primary route of interest beyond laboratory IV use. Human oral bioavailability has not been studied, and formulation challenges created by BAM-15's poor water solubility mean that bioavailability may vary significantly between products depending on the solvent system used.

Intravenous (IV)

A 1 mg/kg intravenous dose was used in rodent pharmacokinetic studies to establish baseline distribution and clearance parameters. IV administration in this context was a research tool, not a proposed route for any therapeutic or self-experimentation use. IV administration of an uncharacterized research compound in humans carries risks that go well beyond those of oral administration and is not a route with any documented human application for BAM-15.

Laboratory Reconstitution

In laboratory settings, BAM-15 is typically dissolved in DMSO (dimethyl sulfoxide) at 20 mg/mL for in vitro work. DMSO is a standard laboratory solvent that is not suitable for direct human use at concentrations required for BAM-15 preparation; it is a laboratory tool, not a human administration solvent. Consumer liquid products from research-chemical vendors use their own solvent systems, which are not standardized and vary by product.

BAM-15 Dosage & Cycle Length

There is no established human dose for BAM-15. This section documents what the preclinical research used and what the research-chemical market offers, not a protocol, not a recommendation, and not a starting point for self-experimentation. BAM-15 has never been tested in a human clinical trial.

Preclinical oral doses used in animal research: 10 mg/kg, 50 mg/kg, and 100 mg/kg in rodents; dose-dependent effects on fat mass and energy expenditure were observed across this range .

Intravenous dose used in pharmacokinetic research: 1 mg/kg in rodents, used to establish baseline distribution and clearance parameters, not a route or dose relevant to any other context.

Research-chemical market formats (not clinical recommendations):

• Capsule products: 50 mg per capsule, typically sold in 3,000 mg total quantities
• Liquid solutions: 100 mg/mL in 30 mL formats (3,000 mg total)

Why animal doses cannot be directly extrapolated to humans:

Rodent-to-human dose conversion is not a simple multiplication. Body surface area scaling, metabolic rate differences, allometric correction (a method that adjusts doses between species based on differences in body size and metabolic scaling), and species-specific pharmacokinetic variation all affect the actual exposure a given mg/kg dose produces. The 10 mg/kg oral dose used in mouse studies does not translate to a numerically equivalent human dose that would be safe or effective. No dose-finding studies in humans have established where any such equivalent might be. Applying preclinical doses to human use is not scientifically valid and carries unknown risks.

Cycle length: Not established. No validated human protocol, loading phase, cycling period, or off-protocol guidance exists for BAM-15.

BAM-15 Vial Sizes, Costs & Quality

BAM-15 is not sold as a pharmaceutical product. It is available from research chemical suppliers and biochemical reagent companies in formats intended for laboratory and research use. What follows describes the market as it currently exists, not an endorsement of any product or supplier.

Common research-grade formats and sizes:

• Powder: 5 mg, 10 mg, 25 mg, 50 mg, and 100 mg quantities (biochemical reagent suppliers)
• Capsule: 50 mg per capsule, 60-capsule formats (3,000 mg total) from consumer-oriented research vendors
• Liquid solution: 100 mg/mL in 30 mL format (3,000 mg total) from consumer-oriented research vendors

Typical cost range:

• Small research quantities (5 mg): approximately $125-175 from biochemical reagent suppliers; these are laboratory-grade quantities, not consumer products
• Larger quantities (50-100 mg): approximately $485-900 from biochemical reagent suppliers
• Consumer-oriented capsule and liquid formats: priced separately, with 3,000 mg total quantity products listed by several vendors

Storage: powder (solid) form:

• Temperature: -20 degrees C for long-term storage
• Shelf life: Up to approximately three years under proper storage conditions
• Light sensitivity: Standard precaution applies; store away from light

Storage: reconstituted or liquid solution:

• Temperature: -20 degrees C or -80 degrees C depending on vendor guidance
• Use window: Approximately six months, depending on formulation and storage conditions

Primary laboratory solvent: DMSO (dimethyl sulfoxide) at 20 mg/mL. BAM-15 has limited water solubility, and DMSO is the standard solvent for laboratory reconstitution. Consumer-format liquid products use their own solvent systems, which vary by vendor and are not standardized.

Normal appearance: BAM-15 powder is a solid that dissolves in DMSO to produce a clear solution. Consumer liquid formulations vary in appearance depending on the solvent system used.

Signs of degradation: Visible particulates inconsistent with the expected appearance of the product, unexpected discoloration, or unusual odor compared to a reference product. Degraded compound should not be used in any context.

Quality Considerations

Synthesis purity specs tell only part of the story. BAM-15 is produced to research-grade specifications (typically 98% or higher by HPLC), which sounds reassuring until you consider what that 2% impurity fraction might contain in a small-molecule organic synthesis context. The synthetic route involves fluorinated aromatic amines and heterocyclic chemistry, and byproducts from these processes are not benign. Biochemical reagent suppliers operate under quality management systems with documented certificates of analysis and traceable manufacturing. Consumer-oriented research chemical vendors operate under no such standardized framework, and the same nominal product can vary substantially in actual content and purity between sellers. When a compound's safety profile is based exclusively on animal data, verifying what is actually in the product is not a secondary concern; it is the primary one. No FDA oversight applies to research chemical manufacturing, so purity verification depends entirely on whether the seller has conducted independent third-party testing and whether those results are made available to the buyer.

BAM-15 Side Effects & Safety

No human safety data exist for BAM-15. The side effect profile below is based on theoretical mechanism-based risks (what mitochondrial uncouplers can do, informed by the DNP history and the pharmacology of the compound class) and animal study findings. It does not represent a confirmed human adverse event profile. The absence of documented human side effects does not mean BAM-15 is safe in humans; it means it has not been studied in humans.

Side Effect Spectrum

Contraindications

No clinical contraindications have been formally established because BAM-15 has never been studied in humans. The following are inferred from mechanism and compound class:

• Active or history of cardiovascular disease, arrhythmia, or hypertension: Mitochondrial uncoupling increases cardiac demand; the cardiovascular burden at human-equivalent doses is unknown
• Liver or kidney disease: The liver is the primary tissue accumulation site in rodent pharmacokinetic studies; hepatic impairment could alter distribution and clearance in unknown ways
• Concurrent use of stimulants, thermogenic agents, or other metabolic modulators: Additive or synergistic thermogenic burden is a theoretical concern with any combination that increases metabolic rate or body temperature
• Use of DNP or other mitochondrial uncouplers: No combination safety data exist; overlapping mechanisms represent a serious unknown risk
• Insufficient data to confirm safety in any human population: BAM-15 has not been studied in any human cohort

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: No safety data exist; mitochondrial function is essential to fetal development; use is not appropriate without medical supervision and is arguably not appropriate at all given the complete absence of human data
• Pediatric use: Not studied in pediatric populations; not appropriate without medical supervision
• Athletes subject to anti-doping rules: BAM-15 is prohibited by WADA under S4 (Hormone and Metabolic Modulators); use constitutes a doping violation
• Individuals in hot environments or performing strenuous physical activity: The combination of BAM-15's thermogenic mechanism and external heat load or exercise-generated heat represents a theoretical hyperthermia risk that cannot be quantified from current data

Red Flags: Stop Use and Seek Medical Attention If

• Core body temperature rises above normal range during or after use
• Abnormal heart rate, chest pain, or palpitations
• Signs of liver stress (yellowing of skin or eyes, abdominal pain, dark urine)
• Severe sweating or inability to regulate body temperature
• Confusion, weakness, or neurological symptoms

Drug and Compound Interactions

No drug-drug or compound-compound interactions have been formally studied for BAM-15 in any published human research. At the mechanistic level, compounds that increase metabolic rate, thermogenesis, or cardiovascular demand (including stimulants, other uncouplers, thyroid hormone, and some weight-loss agents) represent theoretical additive risk when combined with BAM-15's protonophore activity. AMPK activators such as metformin and AICAR share a downstream signaling pathway with BAM-15's secondary mechanism; whether this interaction is synergistic, redundant, or creates unexpected effects is unknown. No combination with other compounds can be considered safe given the complete absence of human safety data for BAM-15 itself.

BAM-15 Research & Studies

Pharmacokinetics & Metabolism

Absorption & Bioavailability

Oral bioavailability of BAM-15 was characterized at 67% in mice across doses of 10, 50, and 100 mg/kg, documented in rodent pharmacokinetic studies . This is relatively high for a small molecule with limited water solubility. Researchers attribute it to BAM-15's lipophilic (fat-soluble) properties, the same properties that allow it to partition into and across biological membranes. Human oral bioavailability has not been studied.

Distribution

The liver is the primary tissue accumulation site in rodent pharmacokinetic studies. Hepatic exposure is higher than systemic plasma concentrations would suggest. Whether this preferential hepatic distribution concentrates the compound where metabolic dysfunction is most relevant, or increases hepatic exposure to a pharmacologically active uncoupler in ways that could cause harm, cannot be determined from preclinical data alone. Distribution to other tissues has not been fully characterized, and data on central nervous system penetration are not available from published sources.

Half-Life

Approximately 1.7 hours in mice, measured from oral dosing studies . The short half-life is cited in the literature as a potential tolerability advantage, because rapid clearance limits the duration of any unwanted uncoupling effects. Animal pharmacokinetic data showed tissue clearance substantially complete by approximately four hours post-dose. Human half-life is unknown.

Metabolism & Elimination

Specific metabolic pathways and elimination routes have not been fully characterized in the published literature available for this article. The short half-life implies relatively rapid metabolic processing. Whether elimination occurs primarily through hepatic metabolism, renal excretion, or other routes cannot be determined from available preclinical data.

Significant data gap: All pharmacokinetic data are from rodent studies. Human absorption, distribution, metabolism, and elimination profiles have not been characterized. Animal-to-human extrapolation for this compound class requires independent validation that does not currently exist.

Mechanistic Research

Protonophore Activity and Mitochondrial Respiratory Uncoupling (Evidence: In vitro and Animal, Kenwood et al., 2014)

BAM-15 was identified and characterized as a protonophore in foundational research that established both its mechanism and its selectivity profile. Studies demonstrated that BAM-15 increases oxygen consumption in isolated mitochondria and intact cells in a concentration-dependent manner, with effects distinguishable from plasma membrane depolarization. The compound's activity was sustained across a range of concentrations without the steep dose-response curve associated with DNP. Researchers attributed this to BAM-15's more selective mitochondrial targeting .

AMPK Activation as a Sustained Metabolic Driver (Evidence: Animal, Alexopoulos et al., 2020)

Beyond the acute uncoupling effect, at least one study identified sustained AMPK activation as an important secondary mechanism contributing to BAM-15's metabolic effects in diet-induced obese mice. AMPK activation occurs when the cellular AMP-to-ATP ratio rises, which uncoupling causes by impairing ATP synthesis. Activated AMPK promotes glucose uptake, fatty acid oxidation, inhibits lipid synthesis, and stimulates mitochondrial biogenesis. This dual mechanism (acute energy expenditure from uncoupling plus sustained AMPK-driven metabolic reprogramming) has been proposed as the reason BAM-15's metabolic effects persist beyond the window predicted by its short half-life .

Selectivity vs. Classic Protonophores (Evidence: In vitro, Kenwood et al., 2014)

A key mechanistic distinction from DNP is BAM-15's behavior at the plasma membrane. DNP is non-selective. It disrupts proton gradients across any lipid bilayer it encounters, including the plasma membrane, causing widespread cellular toxicity. BAM-15 shows preferential activity at the inner mitochondrial membrane at effective concentrations, with no evidence of plasma membrane depolarization in studied concentration ranges. This selectivity is the mechanistic basis for its improved preclinical tolerability profile and is a primary focus of research comparing BAM-15 to earlier uncoupling agents .

Condition-Focused Research

Obesity and Fat Mass Reduction {#research-obesity}

Diet-induced obese mouse models treated with oral BAM-15 showed dose-dependent reductions in fat mass over days to weeks of treatment. The critical distinguishing feature in these studies was the absence of changes in food intake. The animals did not eat less, yet lost fat mass. Lean body mass was preserved throughout the treatment periods studied, and liver triglyceride content also decreased, consistent with the compound's hepatic distribution profile. This combination (fat loss without appetite suppression and without muscle loss) represents a mechanistically distinct profile compared to most established interventions. (Evidence: Preliminary: animal models, Alexopoulos et al., 2020)

Glucose Metabolism and Insulin Sensitivity {#research-glucose}

Multiple preclinical studies have documented improvements in glucose homeostasis in BAM-15-treated animals. The most striking finding is the complete reversal of glucose intolerance and hyperinsulinemia in diet-induced obese mice after approximately three weeks of treatment. This degree of metabolic rescue in an animal model that parallels human metabolic syndrome is considered a strong preclinical signal by researchers in the diabetes and metabolic disease field. The mechanism involves both direct mitochondrial enhancement of glucose oxidation and AMPK-mediated promotion of glucose uptake into peripheral tissues. (Evidence: Preliminary: animal models, Alexopoulos et al., 2020)

Energy Expenditure and Thermogenesis {#research-energy}

Pharmacokinetic studies in mice quantified the acute energy expenditure effect with direct oxygen consumption measurements. A single oral dose produced a measurable rise in whole-body oxygen consumption within one to two hours, with return toward baseline by approximately three hours, tracking the compound's 1.7-hour half-life. This predictable and time-limited energy expenditure effect was reproducible across doses. It is also the most directly validated preclinical finding for BAM-15, measurable in real time rather than inferred from longer-term body composition changes. (Evidence: Preliminary: animal models, Alexopoulos et al., 2020)

Cardiovascular and Endothelial Biology {#research-cardio}

At least one published review addresses BAM-15 in the context of endothelial cell biology. Mitochondrial function in vascular endothelium is an active research area; endothelial cells are highly dependent on mitochondrial health for maintaining vascular tone, barrier function, and inflammatory regulation. Whether BAM-15's uncoupling mechanism has net positive or net negative effects on endothelial function at human-relevant exposures is an open research question. (Evidence: Preliminary: review and early preclinical, PubMed 40429748)

Safety & Tolerability Research

Preclinical safety studies for BAM-15 have not identified significant tissue damage markers or organ toxicity at studied doses in animal models. Tolerability in rodent experiments was reported as good relative to the compound's pharmacological class. The short half-life and tissue clearance profile are cited as contributing to the absence of accumulation-related toxicity seen with longer-acting uncouplers. The safety database for BAM-15 is limited to animal and cell studies; no formal toxicology package comparable to what would be required for a human clinical trial has been published. The long-term safety profile, even in animals, is not fully characterized. The fundamental class risk remains: mitochondrial uncouplers can cause hyperthermia if the proton leak is uncontrolled or if the compound accumulates. BAM-15's preclinical profile is encouraging relative to DNP, but this comparison has never been made in a human context.

Research Limitations

The BAM-15 evidence base has three fundamental gaps that define the limits of what can be claimed. First, no human pharmacokinetic data exist; oral bioavailability, half-life, tissue distribution, and metabolic clearance are known only in mice. Second, no human safety or efficacy data have been published; every metabolic and body composition finding comes from animal models, primarily diet-induced obese mice, and whether these translate to humans is entirely unknown. Third, BAM-15 has not progressed to registered clinical trials as of July 2026; ClinicalTrials.gov lists no completed or active trials for this compound. Published research describes it as a "therapeutic candidate," not an approved or clinically validated compound. These are not minor gaps; they represent the core distinction between a promising research compound and a compound with an established human use case.

Is BAM-15 Legal? Regulatory & Sports Status

Status current as of July 2026. Regulatory classifications are subject to change; this section should be reviewed and re-dated at every article refresh cycle.

FDA status: BAM-15 is not approved by the FDA as a prescription drug, over-the-counter drug, or dietary supplement ingredient. It holds no New Drug Application or Investigational New Drug approval in the publicly available record. It is classified as a research chemical: available for laboratory and research purposes, not for human therapeutic use.

Research Chemical Classification: In most jurisdictions, BAM-15 is available for purchase and use in research laboratory settings. It is not a scheduled controlled substance in the United States under current DEA classifications, but it is also not approved for human use. The absence of scheduling does not confer approval or safety for human administration.

WADA / USADA status: BAM-15 appears on the 2026 WADA Prohibited List under Section S4: Hormone and Metabolic Modulators, specifically as an AMPK activator. It is prohibited in and out of competition, meaning the ban applies at all times, not only during competition periods. Athletes subject to WADA or USADA rules are prohibited from using BAM-15 regardless of context. This WADA classification represents a formal acknowledgment that BAM-15 is being used or perceived as having potential for use in competitive sport contexts, despite the complete absence of approved human therapeutic applications .

Military status: Published sources reference that BAM-15 faces global sport and military bans. Specific military branch policies were not detailed in available sources, but defense organizations have identified BAM-15 as a prohibited compound .

Country-specific notes: No major national drug regulatory authority in North America, Europe, or Asia-Pacific has approved BAM-15 for any human therapeutic indication. It is available from international biochemical reagent suppliers explicitly for laboratory and research use.

Detection: No information on validated human anti-doping detection tests for BAM-15 was identified in published sources. WADA listing typically precedes or accompanies development of detection methodology, but the specific detection window and testing protocol for BAM-15 are not documented in available public sources.

BAM-15 vs. Alternatives

Context: BAM-15 Is Not a Peptide

BAM-15 occupies an unusual position in the research chemical landscape. It is a small molecule, not a peptide, but it is discussed in many of the same communities (biohacking forums, metabolic health research circles, performance optimization communities) where peptide research compounds circulate. The comparisons below reflect that overlapping research and user context.

Mechanistic Predecessor: The DNP Comparison

• BAM-15 vs. DNP (2,4-dinitrophenol): DNP is the compound BAM-15 is most consistently compared against in the published literature. Both are mitochondrial protonophore uncouplers that increase energy expenditure through the same fundamental mechanism: dissipating the proton gradient across the inner mitochondrial membrane. The critical differences are selectivity and pharmacokinetics. BAM-15 shows more selective mitochondrial targeting with no evidence of plasma membrane depolarization at effective doses, and its short half-life of approximately 1.7 hours in mice limits accumulation. DNP is associated with numerous deaths from uncontrolled hyperthermia and remains a dangerous compound. BAM-15's preclinical profile appears substantially safer, but this comparison has never been made in humans.

Metabolic Modulator Comparisons

MOTS-c

MOTS-c is a mitochondrially derived peptide that activates AMPK through a completely different mechanism; it is produced endogenously by the mitochondrial genome in response to metabolic stress. Both BAM-15 and MOTS-c converge on AMPK activation as a downstream effect, and both are in the preclinical research phase with no approved human applications. MOTS-c is a peptide that requires injection; BAM-15 is a small molecule with oral bioavailability in animal models. The shared AMPK connection has led to their co-discussion in mitochondrial research contexts, but the compounds are mechanistically distinct.

GLP-1 Receptor Agonists (semaglutide, tirzepatide)

GLP-1 and dual GIP/GLP-1 agonists are the current dominant pharmacological approach to obesity management with strong human clinical evidence and FDA approval. Their mechanism is appetite suppression and glycemic control, fundamentally different from BAM-15's energy expenditure approach. GLP-1 agonists work by reducing how much the person eats; BAM-15 works by increasing how much energy the person burns. From an evidence standpoint, this comparison is not between equals. GLP-1 agonists have robust human clinical trial data and regulatory approval. BAM-15 does not.

Tesamorelin

Tesamorelin is a growth hormone-releasing hormone analog with clinical data and FDA approval for HIV-associated lipodystrophy. It reduces visceral fat through GH axis stimulation rather than energy expenditure uncoupling. In metabolic health communities, tesamorelin and BAM-15 are sometimes discussed in a complementary framing: tesamorelin addressing visceral fat via hormonal mechanisms and BAM-15 theoretically addressing energy expenditure. This is a conceptual pairing without any published combination evidence.

Comparison Table

Build Your BAM-15 Mitochondrial Uncoupler Protocol

BAM-15 FAQs

What is BAM-15?

BAM-15 is a synthetic small-molecule research compound classified as a mitochondrial protonophore uncoupler; it is not a peptide, despite appearing on some vendor sites under peptide categories. It works by increasing the permeability of the inner mitochondrial membrane to protons, which forces cells to burn more fuel as heat rather than storing it as ATP. It is currently in the preclinical research phase, with all published data from animal and cell studies.

What does BAM-15 do?

In animal models, BAM-15 increases whole-body energy expenditure, reduces fat mass, improves insulin sensitivity, and reverses markers of glucose intolerance, all without reducing food intake or causing significant lean muscle loss. These outcomes have been consistently observed in diet-induced obese mouse models. Whether any of these effects occur in humans has not been studied in any published clinical trial.

How long does BAM-15 take to work?

In mouse pharmacokinetic studies, measurable increases in oxygen consumption appear within one to two hours of oral administration and return toward baseline by approximately three hours, consistent with the compound's short half-life of roughly 1.7 hours in rodents. Longer-term metabolic effects on body composition and insulin sensitivity were observed over days to weeks in animal studies. Human onset and duration of effects are unknown.

What is the typical dose of BAM-15?

There is no established human dose for BAM-15. Animal studies used oral doses of 10, 50, and 100 mg/kg in rodents; these cannot be directly extrapolated to human doses without validated clinical dose-finding studies, which do not exist. Research-chemical vendors sell BAM-15 in 50 mg capsule formats and 100 mg/mL liquid solutions, but these are research-grade products without clinical dosing validation.

Is BAM-15 legal?

BAM-15 is not approved for human use by the FDA or any comparable international regulatory authority, but it is not a scheduled controlled substance in the United States under current DEA classifications. It is available for purchase as a research chemical for laboratory use. For athletes, BAM-15 is unambiguously prohibited; it appears on the 2026 WADA Prohibited List under S4 Hormone and Metabolic Modulators, banned both in and out of competition.

Can BAM-15 be taken orally?

In rodent studies, BAM-15 demonstrated 67% oral bioavailability, which is relatively high for a compound in this chemical class. Research-chemical vendors sell it in oral formats including capsules and liquid solutions. Human oral bioavailability has not been studied, and BAM-15's limited water solubility creates formulation challenges that vary by product.

How does BAM-15 compare to DNP?

Both BAM-15 and DNP are mitochondrial protonophore uncouplers that increase energy expenditure by dissipating the proton gradient across the inner mitochondrial membrane. DNP is non-selective and disrupts multiple membrane types, causing widespread cellular toxicity that led to numerous deaths from hyperthermia when used as a weight-loss drug in the 1930s. BAM-15 shows more selective mitochondrial targeting and a shorter half-life in animal studies, with a more favorable preclinical tolerability profile, but no direct human comparison exists and the theoretical hyperthermia risk applies to any compound with this mechanism.

Why is BAM-15 on the WADA prohibited list if it has no human clinical trials?

WADA lists compounds based on their pharmacological profile and potential for performance enhancement, not only on whether they have received regulatory approval or been studied in humans. BAM-15's mechanism (increasing energy expenditure and improving metabolic efficiency) is consistent with performance enhancement potential, particularly in endurance sports. WADA's inclusion of BAM-15 under S4 (AMPK activators) reflects a preemptive prohibition based on mechanism and the evidence that compounds with this profile confer metabolic advantages in animal models. Athletes should treat WADA listing as an absolute bar regardless of the compound's approval status.

Is BAM-15 the same as a peptide?

No. BAM-15 is a small-molecule organic compound with no amino acid sequence and no peptide bonds. It belongs to the oxadiazolopyrazine chemical class. Some vendors list it alongside peptides due to community overlap in research-chemical markets, but the classification is incorrect. It is a synthetic fluorinated aromatic compound: a fundamentally different type of molecule from any peptide, including the other compounds in the MPP research compound library.

BAM-15: Final Thoughts

BAM-15 is one of the most mechanistically interesting research compounds in the metabolic health space right now, and one of the most misunderstood. It is not a peptide, it has no approved human use, and every compelling result attributed to it in published science comes from animal or cell studies. That is not a reason to dismiss it. It is a reason to understand it clearly, which is what this guide has tried to do.

The preclinical picture is genuinely interesting. A compound that increases energy expenditure without appetite suppression, preserves lean mass in obese animal models, reverses glucose intolerance within weeks, and clears the body within hours represents a mechanistically distinct tool compared to anything currently available with regulatory approval. The comparison to DNP (which killed people) is useful not to scare, but to situate where BAM-15 sits: it is a better-engineered version of a mechanism that has been understood for nearly a century. Whether that engineering improvement translates to human safety and efficacy is the open question the preclinical data cannot answer.

Three things warrant direct acknowledgment before treating BAM-15 as anything other than a research compound. First, WADA has prohibited it; athletes are not in a gray area. Second, the theoretical risk of uncontrolled hyperthermia is not a footnote; it is the defining class-level concern for every mitochondrial uncoupler, and BAM-15 has not been studied in humans under any of the conditions that would amplify that risk. Third, no human pharmacokinetic data exist; the dose, bioavailability, and clearance profile that looked promising in mice may be entirely different in human physiology.

If you are exploring metabolic health compounds and the mechanisms covered in this guide are relevant to your research interests, MyPeptidePal covers the broader landscape of metabolic and mitochondrial research compounds, including compounds with more established human evidence profiles. Use the app to understand how BAM-15 sits alongside other options, and to build informed context around any protocol you are considering with a qualified healthcare provider.

References

1. Kenwood, B. M., Weaver, J. L., Bajwa, A., et al., & Hoehn, K. L. (2014). Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane. Molecular Metabolism, 3(2), 114-123.

2. Alexopoulos, S. J., Chen, S. Y., Brandon, A. E., Salamoun, J. M., Byrne, F. L., Peterson, E. J., Crowther, G., Turner, N., & Hoehn, K. L. (2020). Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice. Nature Communications, 11(1), 2397.

3. Green, D. (2024). Why BAM-15 faces global sport and military bans. BSCG.

4. BAM-15 compound entry: chemical identity, CAS number, molecular formula, and structural data. PubChem, CID 565708.

5. Salamoun, J. M., & Hoehn, K. L. (2023). BAM-15 as a therapeutic candidate: mitochondrial uncoupling and metabolic disease. Frontiers in Endocrinology, 14, 1252141.

6. Brennan, T., Bhatt, D., & Chen, H. (2024). Beneficial effects of simultaneously targeting metabolic modulators. Clinical Science, 138(4), 173.

7. Jang, W. B., et al. (2025). Targeting mitochondrial dysfunction to prevent endothelial dysfunction and atherosclerosis in diabetes: focus on the novel uncoupler BAM15. International Journal of Molecular Sciences.